Pyrukynd (mitapivat) prior authorization
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
Rules for prior authorization and reauthorization of Pyrukynd (mitapivat) for treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency; applicable to UnitedHealthcare pharmacy benefit administration.
No material clinical or coverage changes in this revision.
Coverage Criteria for Pyrukynd (mitapivat)
Initial Authorization
Covered when ALL of the following are met
Authorization will be issued for 12 months
Reauthorization
Reauthorization covered when ONE of the following is met
Authorization will be issued for 12 months
Authorization will be issued for 4 weeks
There are no additional coverage exclusions specified beyond the diagnostic and indication requirements listed in the criteria. Coverage is contingent on meeting the stated diagnostic rule — a documented diagnosis of pyruvate kinase (PK) deficiency — and the indication that Pyrukynd is being used for the treatment of hemolytic anemia. Requests that do not meet those requirements will not meet initial authorization criteria.
Initial Therapy
Initial Therapy
Initial therapy coverage rule
Authorization will be issued for 12 months
Reauthorization / Continuation Therapy
Reauthorization / Continuation Therapy
Reauthorization pathways
12-month authorization
4-week authorization
Provider Actions and Prior Authorization Requirements
Prior authorization required — initial requests must document PK deficiency and hemolytic anemia
Prior authorization is required for all initial requests for Pyrukynd (mitapivat). Initial approval is issued only when both criteria are met: (1) a diagnosis of pyruvate kinase (PK) deficiency, AND (2) use for the treatment of hemolytic anemia. Initial authorizations are issued for 12 months. Include these diagnostic and indication details on the PA request and verify member benefit/plan rules may affect coverage.
- Must document diagnosis: pyruvate kinase (PK) deficiency.
- Must document intended use: treatment of hemolytic anemia.
- Initial authorization duration: 12 months.
- Confirm member-specific benefit plan and any state/federal mandates may affect coverage.
Prior authorization — reauthorization requires evidence of response for 12-month approvals
For reauthorization, submit documentation demonstrating a positive clinical response to Pyrukynd; when that documentation is provided, authorization will be issued for 12 months. If documentation does not demonstrate a positive response, the policy allows a shorter authorization to permit dose titration and potential discontinuation.
- If positive clinical response documented → reauthorization duration: 12 months.
- If no evidence of positive response → allow dose titration with discontinuation (see limited approval duration).
Automated approval/re-approval may be used based on claims, meds, and ICD-10 logic
UnitedHealthcare may use automated approval and reauthorization processes based on prior claim/medication history, diagnosis codes (ICD-10), and claim logic; use of these automated processes varies by program or therapeutic class.
- Automated approvals may be granted using previous claims or medication history.
- ICD-10 diagnosis codes and claim logic can be used in automated decisioning.
- Application of automated approval/re-approval varies by program/therapeutic class.
Reauthorization documentation must show positive clinical response; otherwise 4-week titration approval
For reauthorization requests, document a positive clinical response to Pyrukynd; if the request lacks sufficient evidence of response, the policy permits a limited 4-week authorization to allow dose titration and discontinuation of therapy.
- Documentation must show positive clinical response to receive a 12-month reauthorization.
- If documentation is insufficient to show response, a 4-week authorization may be issued to allow dose titration and discontinuation.
Denial triggers for initial requests — missing PK deficiency diagnosis or treatment intent
Initial authorization will be denied if the request does not include a diagnosis of pyruvate kinase (PK) deficiency or does not indicate the medication is being used to treat hemolytic anemia.
- Missing diagnosis of PK deficiency is a denial trigger.
- Lack of documentation that the drug is being used for treatment of hemolytic anemia is a denial trigger.
Definitions
Background
Mitapivat (Pyrukynd) is covered under this policy specifically for adults with a documented diagnosis of pyruvate kinase (PK) deficiency when used to treat hemolytic anemia. For initial authorization, both the diagnosis of PK deficiency and use for hemolytic anemia must be documented; when these criteria are met, authorization is issued for 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.